CBD research authorization is granted to Elixinol in New York

Share this:

CBD maker Elixinol has been granted Processor Research Partner Authorization by the New York (U.S.) Department of Agriculture and Markets, which is actively supporting hemp initiatives up and down the value chain.

“We are excited to continue to scale our production and efficiency, and support the state of New York’s economy while doing so,” said Gabriel Ettenson, President and Co-Founder of Elixinol.

Research focus

The authorization lets Elixinol carry out research that advances the promotion of safe, quality assured hemp extract and hemp-derived CBD products that are manufactured, tested, and labeled under U.S. Food and Drug Administration regulations for dietary supplements.

Under guidelines of the Research Partner program, Elixinol is to file an annual report summarizing the results of its research into the sale, distribution, transportation and processing of hemp and products derived from hemp.

State supports hemp

Elixinol took advantage of a short window Dec. 4-28, 2019 to submit its application for the authorization. New York last year started allowing the processing and manufacture of hemp extract and hemp-derived CBD products under its state program.

Hemp stakeholders in New York are taking advantage of an enlightened and supportive approach to the crop by state officials. The state last year earmarked $650,000 for a $3.2 million hemp processing plant near Binghamton in the south central part of the state, and set aside $2 million in last year’s budget for a state-run hemp seed certification program. The state in 2017 established a $5 million industrial hemp processing grant program for qualified projects related to hemp production.

Get Hemp Industry Updates

* indicates required

Newsletter Signup

Subscribe to our FREE email newsletter & get the latest hemp industry news directly in your inbox.

* indicates required
Scroll to Top